ASH 2023 | Current landscape of treatment for SCD: an update from ASH 2023
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, discusses the current treatment landscape for patients with sickle cell disease (SCD). This includes hydroxyurea, pyruvate kinase activators, small molecules that increase the oxygen affinity of hemoglobin, antibody-based treatments, and recently approved gene therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Advisory board: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Research Funding: Novartis, Forma Therapeutics, GBT/Pfizer
Speakers Bureau: GBT/Pfizer
